Sartorius AG (ETR:SRT) has received an average recommendation of “Hold” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is €114.88 ($133.58).
Several research analysts have commented on SRT shares. Deutsche Bank set a €125.00 ($145.35) price objective on shares of Sartorius and gave the company a “neutral” rating in a research report on Friday, July 13th. Kepler Capital Markets set a €78.00 ($90.70) price objective on shares of Sartorius and gave the company a “neutral” rating in a research report on Tuesday, July 24th. Hauck & Aufhaeuser set a €93.00 ($108.14) price objective on shares of Sartorius and gave the company a “sell” rating in a research report on Thursday, July 26th. Warburg Research set a €141.00 ($163.95) price target on shares of Sartorius and gave the stock a “neutral” rating in a report on Tuesday, July 24th. Finally, HSBC set a €96.00 ($111.63) price target on shares of Sartorius and gave the stock a “sell” rating in a report on Wednesday, July 25th.
SRT traded down €2.50 ($2.91) during trading on Thursday, hitting €117.50 ($136.63). 371 shares of the stock traded hands.
Sartorius Company Profile
Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.
Further Reading: Hedge Funds Explained
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.